Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Idelalisib in NSCLC
NCT03257722Phase 2Terminated
- Sponsor
- Asha Nayak
- Start
- Sep 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idelalisib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Asha Nayak. Primary endpoint: Dose-Limiting Toxicity at 9 weeks. Started Sep 2017; status: terminated.
02
Drugs
idelalisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03257722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257722.